Home > Back to Publisher > Report Information

Anti-Infectives: World Market, 2nd. Ed., Vol. I: Antifungals

Kalorama Information
March 1, 2007
150 Pages - SKU: KLI1399435

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Part of a three volume series.
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections.

This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been a factor. These are part of the factors that have lead to nearly 6-billion dollar antifungal drug industry.

Anti-Infectives, Second Edition, Volume I: Antifungals is a comprehensive review of the market for anti fungal drugs. This is the first volume of Kalorama Information’s 2nd edition of its popular three-part series on anti-infective markets. The report focuses on two segments of antifungal treatment: systemic and topical. The report covers both currently marketed and late stage development antifungal products in detail.

For both the systemic and topical antifungal markets, this report includes:

U.S. and World Revenues
Forecasts to 2011.
Overview and Incidence Data
Description of Products on the Market
Review of Products in Development
Competitive Analysis of Leading Providers.
10 Key Issues and Trends facing the antifungal industry

Revenues for each segment were generated using dollar and unit sales for each product. All market data pertain to the world market at the manufacturers’ level. Revenues and market share of major brands such as Lamisil, Diflucan, Sporanox, Cancidas, Vfend, and others are included.

Competitive analysis is provided for the year 2006. The forecasted market analysis for 2004-2011 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

As part of Kalorama's trusted information-gathering process, the information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information and developing forecasts.

For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

CHAPTER ONE: Executive Summary

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: Introduction

Overview
- Introduction to Pathogens
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
  - Infecting Organism
  - Antibiotic Sensitivity Testing
  - Site of Infection
  - Host Defenses and Organ Function
  - Antibiotic Pharmcokinetics
  - Monitoring Therapy
- Combination Therapy and Prophylactic Use
- Fungal Infections
- Types of Fungal Infections
  - Superficial
  - Systemic
    - Histoplasmosis
    - Coccidioidomycosis
    - Blastomycosis
  - Demographics and Statistics

CHAPTER THREE: Systemic Antifungal Drugs

Overview
Description of Products
- Allylamines
- Terbinafine (Lamisil - Novartis)
- Azoles
- Fluconazole (Diflucan - Pfizer)
- Ketoconazole (Nizoral, Johnson & Johnson)
- Miconazole (Monistat, Johnson & Johnson)
- Itraconazole (Sporanox, Johnson & Johnson)
- Posaconazole (Noxafil, Schering-Plough)
- Virconazole (Vfend, Pfizer)
- Polyene Macrolides
- Amphotericin B (Ambisome, Astellas; Abelcet, Enzon; Fungizone, Apothecon).
- Griseofluvin (Fulvicin, Schering)
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Flucytosine (Ancoban, Valeant)
- Echinocandins
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

CHAPTER FOUR: Topical Antifungal Drugs

Overview
Description of Products
- Allylamines
- Naftifine (Naftin, Allergan)
- Terbinafine (Lamisil - Novartis)
- Butenafine (Mentax, Bertek)
- Azoles
- Miconazole (Monistat -Derm, OrthoDermatological)
- Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
- Ketoconazole (Nizoral, J&J; Xolegel, Barrier Therapeutics)
- Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
- Econazole (Spectazole, Ortho Dermatological)
- Sulconazole (Exelderm, Westwood-Squibb)
- Terconazole (Terazol, Ortho Dermatological)
- Polyene Macrolides
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
- Selenium sulfide (Selsun, Chattem Inc)
- Amorolfine (Loceryl, Roche)
- Alcortin (Iodoquinol, hydrocortisone, Primus Pharmaceuticals)
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis

CHAPTER FIVE: Issues and Trends Affecting the Antifungal Market

Introduction
Fungal Infections and Immunocompromised Patients
Reimbursement
Infection Imaging
Expanded Use of Azoles
Drug Resistance and Interactions
Standardized Susceptibility Testing
Generic Impact and Availability
Importance of Drug Delivery
Rx-to-OTC Switches
The Antifungal Market and Enchiocandins

chapter six: Antifungal Drugs: Total Market Size and Forecast

Overview
Total market Size and Forecast

CHAPTER SEVEN: Corporate Profiles

Introduction
Astellas Pharma Inc
Barrier Therapeutics, Inc
Johnson & Johnson Group
Merck & Company, Inc
Novartis Pharmaceuticals Corporation
Pfizer, Inc
Schering-Plough Corporation

CHAPTER EIGHT: Company Directory

table of exhibits

Chapter One: Executive Summary

Table 1-1: The World Market for Antifungal Drugs 2004-2011
Figure 1-1: The World Market for Antifungal Drugs 2004-2011

Chapter Two: Introduction

Table 2-1: Estimated World and U.S. Incidence of Fungal Infections (thousands)
Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
Table 2-2: World Population by Selected Geographical Region, 2006-2050
Figure 2-2: World Population by Selected Geographical Region, 2006-2050
Table 2-3: Estimated World Population by Age and Geographical Region, 2006
Figure 2-3: Estimated World Population by Age and Geographical Region, 2006
Table 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
Figure 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006

Chapter Three: Systemic Antifungal Drugs

Table 3-1: Allylamines
Table 3-2: Azoles
Table 3-3: Polyene Macrolides
Table 3-4: Miscellaneous Antifungals
Table 3-5: New Generic Drug Approvals for Systemic Antifungals, United States, 2004-2006
Table 3-6: Systemic Antifungal Drugs in Development
Table 3-7: The Market for Systemic Antifungal Drugs 2004-2011
Figure 3-1: Systemic Antifungal Drug Market 2004-2011
Table 3-8: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2004-2010
Figure 3-2 : Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2004-2010
Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2004-2011
Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2006 and 2011
Table 3-9: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2006
Table 3-10: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2006
Table 3-11: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
Table 3-12: Systemic Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 3-8: Systemic Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
Table 3-13: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
Figure 3-9: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006

Chapter Four: Topical Antifungal Drugs

Table 4-1: Allyamines
Table 4-2: Topical Azoles
Table 4-3: Polyene Macrolides
Table 4-4: Miscellaneous Antifungals
Table 4-5: New Generic Drug Approvals for Topical Antifungals,
United States, 2004-2006
Table 4-6: Topical Antifungal Drugs in Development
Table 4-7: Topical Antifungal Drug Market, 2004-2011
Figure 4-8: Topical Antifungal Drug Market, 2004-2011
Table 4-8: Topical Antifungal Drug Market, 2004-2011
Figure 4-9: Topical Antifungal Drug Market by Product Type - Revenues, 2004-2011
Figure 4-10: Topical Antifungal Drug Market by Product Type -Percent Distribution, 2004-2011
Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2006 and 2011
Table 4-9: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2006
Table 4-10 : Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2006
Table 4-11: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
Table 4-12: Topical Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 4-8: Topical Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
Table 4-13: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
Figure 4-9: Topical Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006

Chapter Five: Issues and Trends Affecting the

Antifungal Market
Table-5-1: New Generic Drug Approvals for Antifungals, United States, 2004-2006
Table 5-2: Selected Antifungal Rx-to-OTC Switches

Chapter Six: Antifungal Drugs: Total Market

Size and Forecast
Table 6-1: The World Market for Antifungal Drugs 2004-2011
Figure 6-1: The World Market for Antifungal Drugs 2004-2011
Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2004-2011
Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2004-2011
Figure 6-3: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2006 and 2011

More Global Infectious Diseases Reports

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

Global Infectious Disease Treatment Market 2011-2014 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections) by Kalorama Information
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, ...

Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...

See all reports like this >>

Anti-Infectives: World Market, 2nd. Ed., Vol. I: Antifungals

Share this report

Other tasks

Research Assistance

Related Markets

Infectious Diseases Reports

Free Alert Me service